Drug Trial Radar · NCT02419417
Study of BMS-986158 in Subjects With Select Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Jun 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Jun 19, 2015
Primary completion
Mar 17, 2021
Study completion Mar 17, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Conditions
- Advanced Tumors
Interventions
BMS-986158Drug
Specified dose on specified days
NivolumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: From first dose to 30 days following last dose (up to approximately 29 months)
- Number of Participants With Abnormal Hepatic Test ValuesTime frame: From first dose to 30 days following last dose (up to approximately 29 months)
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
City Of Hope National Medical Center
Duarte, California
University Of Colorado
Aurora, Colorado
Dana Farber Cancer Institute.
Boston, Massachusetts
Oregon Health & Science University
Portland, Oregon
Univ. Of Pa
Philadelphia, Pennsylvania
Institute for Translational Oncology Research-ITOR
Greenville, South Carolina
Nucleus Network
Melbourne, Victoria, Australia
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Local Institution
Lyon, France
Local Institution
Villejuif, France
H. Univ. Vall dHebron
Barcelona, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.